KETOROLAC TROMETHAMINE | A210616 | CHARTWELL RX SCIENCES LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Fox Rothschild LLP FDA-2020-P-0745 · 4 docket documents Fox Rothschild LLP filed this citizen petition requesting that FDA designate ANDA 074754 held by Teva Pharmaceuticals USA Inc. as the reference standard for Ketorolac Tromethamine Tablets, 10 mg, to replace the current reference standard under ANDA 074761 held by Mylan Pharmaceuticals Inc., which is | 505(q) | 2020-02-12 | Granted | Fox Rothschild LLP |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1764
per ea
Lowest NADAC/Unit
$0.1764
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 62135081160KETOROLAC 10 MG TABLET | $0.1764 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.